LIFECORE BIOMEDICAL, INC. Legal Fees
LIFECORE BIOMEDICAL, INC. (LFCR) reported Legal Fees of $0 for the 12-month period ending 2022-05-29, per its 10-K/A filed 2023-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2024-03-20
- LIFECORE BIOMEDICAL, INC. legal fees for the quarter ending 2022-05-29 was $0.00.
- LIFECORE BIOMEDICAL, INC. legal fees for the quarter ending 2022-02-27 was $0.00.
- LIFECORE BIOMEDICAL, INC. legal fees for the quarter ending 2021-11-28 was $0.00, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. legal fees for the quarter ending 2021-05-30 was -$1.76M.
- LIFECORE BIOMEDICAL, INC. legal fees for fiscal 2022 was $0.00.
- LIFECORE BIOMEDICAL, INC. legal fees for fiscal 2021 was $0.00.
- LIFECORE BIOMEDICAL, INC. legal fees for fiscal 2020 was $0.00.
- LIFECORE BIOMEDICAL, INC. legal fees for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Legal Fees 3 month | Legal Fees 6 month | Legal Fees 9 month | Legal Fees 12 month | Legal Fees 12 month as first filed |
|---|---|---|---|---|---|
| 2022-05-29 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | $0.00 10-K/A · filed 2023-03-16 | |
| 2022-02-27 | $0.00 10-Q · filed 2022-04-07 | $0.00 derived: sum of 2 quarters · filed 2022-04-07 | $0.00 10-Q · filed 2022-04-07 | ||
| 2021-11-28 | $0.00 10-Q · filed 2022-01-07 | $0.00 10-Q · filed 2022-01-07 | |||
| 2021-05-30 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$1.76M derived: sum of 2 quarters · filed 2024-03-20 | $0.00 derived: sum of 3 quarters · filed 2024-03-20 | $0.00 10-K · filed 2024-03-20 | $1.76M 10-K · filed 2021-07-29 |
| 2021-02-28 | $0.00 10-Q · filed 2022-04-07 | $1.76M derived: sum of 2 quarters · filed 2022-04-07 | $1.76M 10-Q · filed 2022-04-07 | ||
| 2020-11-29 | $1.76M 10-Q · filed 2022-01-07 | $1.76M 10-Q · filed 2022-01-07 | |||
| 2020-05-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | $0.00 10-K/A · filed 2023-03-16 | |
| 2020-02-23 | $0.00 10-Q · filed 2021-04-08 | $0.00 derived: sum of 2 quarters · filed 2021-04-08 | $0.00 10-Q · filed 2021-04-08 | ||
| 2019-11-24 | $0.00 10-Q · filed 2021-01-07 | $0.00 10-Q · filed 2021-01-07 | |||
| 2019-05-26 | $0.00 10-K · filed 2021-07-29 | ||||
| 2018-05-27 | $600.00K 10-K · filed 2019-08-01 | $639.00K 10-K · filed 2018-08-09 | |||
| 2017-05-28 | $2.10M 10-K · filed 2019-08-01 | ||||
| 2016-05-29 | $542.00K 10-K · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |